Novavax, Inc. (NASDAQ:NVAX) Director Sells $43,200.00 in Stock

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 5,400 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the sale, the director now owns 51,760 shares of the company’s stock, valued at $414,080. This trade represents a 9.45 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

Novavax Stock Performance

NASDAQ:NVAX opened at $8.57 on Friday. Novavax, Inc. has a 52 week low of $3.53 and a 52 week high of $23.86. The firm has a 50-day moving average price of $8.71 and a two-hundred day moving average price of $11.38. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -3.79 and a beta of 2.02.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.07. The business had revenue of $84.51 million for the quarter, compared to analysts’ expectations of $65.80 million. During the same period in the previous year, the business posted ($1.26) earnings per share. The business’s revenue was down 54.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Novavax, Inc. will post -1.44 earnings per share for the current year.

Institutional Investors Weigh In On Novavax

A number of hedge funds have recently made changes to their positions in NVAX. Banque Cantonale Vaudoise increased its holdings in Novavax by 500.0% during the second quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 2,500 shares during the last quarter. Amalgamated Bank increased its stake in shares of Novavax by 26.9% during the 2nd quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 1,036 shares during the last quarter. Signaturefd LLC raised its holdings in shares of Novavax by 214.5% in the 2nd quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 3,874 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Novavax by 38.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 1,598 shares during the last quarter. Finally, Midland Wealth Advisors LLC bought a new position in Novavax during the second quarter valued at $152,000. 53.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

NVAX has been the topic of a number of analyst reports. B. Riley restated a “buy” rating and issued a $26.00 target price (up previously from $23.00) on shares of Novavax in a report on Thursday, October 10th. Jefferies Financial Group lowered their price objective on Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a research note on Wednesday, October 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $19.00 target price on shares of Novavax in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $17.83.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.